Global Microbiome Therapeutics Market Report and Forecast 2025-2034

Microbiome Therapeutics Market Overview

Microbiome therapeutics are innovative treatments that leverage the human microbiome the diverse community of microorganisms in the body to prevent or treat diseases. These therapies aim to restore microbial balance and enhance health, particularly in gastrointestinal, metabolic, immune, and neurological disorders. They include live biotherapeutic products (LBPs), prebiotics, postbiotics, and microbiome-derived metabolites. Advances in next-generation sequencing, bioinformatics, and synthetic biology are accelerating their development. As research deepens and regulatory frameworks evolve, microbiome therapeutics are emerging as a promising frontier in personalised medicine and targeted disease treatment.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Microbiome Therapeutics Market Growth Drivers

Regulatory Approvals and Expanding Applications to Drive Market Growth

The increasing prevalence of Clostridioides difficile infection (CDI) and rising demand for microbiome-based therapeutics are key drivers of market growth. Additionally, regulatory support, including FDA Fast Track Designation, accelerates innovation in this sector. For instance, in January  2024, Seres Therapeutics, Inc. announced key updates on VOWST, the first FDA-approved orally administered microbiome therapeutic, and the advancement of SER-155, designed to prevent GI-associated bacterial infections and graft-versus-host disease (GvHD). These advancements position microbiome-based therapeutics as a mainstream treatment approach, enhancing market adoption. The commercial success of VOWST, combined with SER-155’s potential, is expected to drive investment, expand indications, and accelerate market growth through 2030.

Surge in Research Initiatives to Boost Microbiome Therapeutics Market Demand

The need for microbiome-preserving antibiotics and increasing research on antibiotic-associated dysbiosis are fueling innovations in microbiome therapeutics. For instance, in October  2024, Acurx Pharmaceuticals, Inc. presented Phase 2b trial data at IDWeek™ 2024, demonstrating that ibezapolstat, a novel antibiotic, had comparable efficacy to vancomycin but with superior microbiome outcomes. Patients treated with ibezapolstat showed higher beneficial bacteria levels and improved bile acid metabolism, key indicators of microbiome health. These findings support the development of next-generation antibiotics that minimize microbiome disruption, reinforcing the market shift toward microbiome-friendly therapeutics. As awareness and regulatory support increase, demand for such innovative antibiotics is expected to drive global market expansion.

Microbiome Therapeutics Market Trends

Microbiome Therapeutics Market Segmentation

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 
Microbiome Therapeutics Market Share

Microbiome Drugs to Dominate the Segment by Type

Microbiome drugs are set to dominate the market due to their targeted, scalable, and commercially viable nature. Unlike Faecal Microbiota Transplantation (FMT), microbiome drugs offer precise formulations, controlled dosing, and regulatory approval pathways, making them preferable for widespread clinical use. Advances in synthetic biology, next-generation probiotics, and live biotherapeutic products (LBPs) are driving R&D investments. With the increasing prevalence of gastrointestinal and metabolic disorders, along with strong pharmaceutical industry backing, microbiome drugs are expected to lead market growth, offering safer and more effective treatments with long-term commercial viability.

Oral Route to Lead the Microbiome Therapeutics Market Segmentation by Route of Administration

The oral route is poised to lead the market, owing to its high patient compliance, non-invasiveness, and ease of large-scale production. Oral microbiome therapeutics, including capsules and powders, are favoured for their convenience, stability, and controlled release mechanisms. With technological advancements in oral drug delivery, such as enteric-coated and targeted-release formulations, the segment is set to expand. The growing demand for gut microbiome modulation in conditions like inflammatory bowel disease and metabolic disorders further strengthens its dominance. As regulatory frameworks evolve, oral microbiome drugs will continue driving market growth and accessibility in the coming years.

Inflammatory Bowel Disease to Dominate the Microbiome Therapeutics Market by Application

Inflammatory bowel disease (IBD) is expected to be the dominant segment in microbiome therapeutics applications, driven by the rising global prevalence of Crohn’s disease and ulcerative colitis. Current treatments, including immunosuppressants and biologics, have limitations, prompting demand for microbiome-based alternatives that restore gut microbiota balance. As per the analysis by Expert Market Research, the inflammatory bowel disease treatment market is anticipated to grow at a CAGR of 5.71% during the forecast period of 2025-2034.  Advances in microbiome research and live biotherapeutic products (LBPs) are accelerating IBD-specific drug development. As clinical trials gain momentum and regulatory approvals expand, microbiome therapeutics for IBD will see strong adoption, offering targeted, long-term solutions for patients, while attracting pharmaceutical investments and research funding to further advance treatment efficacy.

Hospitals and Clinics to Hold a Substantial Microbiome Therapeutics Market Value for Segmentation by End User

Hospitals and clinics are projected to hold the largest market share, driven by rising hospital-based microbiome treatment adoption, clinical trials, and advanced healthcare infrastructure. These facilities are at the forefront of FMT procedures and microbiome drug administration, ensuring regulatory compliance and patient safety. With the growing incidence of gastrointestinal disorders and infections, hospitals are investing in microbiome-based treatments to enhance patient outcomes. Additionally, increased collaborations between hospitals, biotech firms, and research institutions are further strengthening this segment’s role in driving innovation, regulatory advancements, and broader market acceptance of microbiome therapeutics.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Microbiome Therapeutics Market Analysis by Region

North America is poised to dominate the market, driven by strong R&D investments, advanced healthcare infrastructure, and rising demand for precision medicine. The presence of leading biotech firms and pharmaceutical companies accelerates innovation in gut microbiome-based therapies. Regulatory support from the FDA and increasing awareness of microbiome-targeted treatments for metabolic, gastrointestinal, and immune disorders further fuel market growth. With expanding clinical trials and collaborations between academia and industry, North America remains at the forefront of microbiome-based drug development, shaping the future of personalised medicine and therapeutic advancements in this emerging sector.

Leading Players in the Microbiome Therapeutics Market

Other key players in the market include Verb Biotics LLC., Vedanta Biosciences, Inc., Ferring Pharmaceuticals Inc., Seres Therapeutics Inc., and Caelus LLC, COST-BRY Pty. Ltd. (BiomeBank). 

Key Questions Answered in the Microbiome Therapeutics Market

• What was the global microbiome therapeutics market value in 2024? 
• What is the global microbiome therapeutics market forecast outlook for 2025-2034?
• What is market segmentation based on type?
• What is market segmentation based on the route of administration?
• What is market segmentation based on application?
• What is market segmentation based on end users?
• What are the major factors aiding the global microbiome therapeutics market demand?  
• How has the market performed so far and how is it anticipated to perform in the coming years? 
• What are the market's major drivers, opportunities, and restraints?
• What are the major global microbiome therapeutics market trends?
• Which type will lead the market segment?  
• Which route of administration will lead the market segment?  
• Which application will lead the market segment? 
• Which end user will lead the market segment?  
• Who are the key players involved in the global microbiome therapeutics market? 
• What is the patent landscape of the market? 
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?